Otelixizumab
Results: 2
| # | Item |
|---|---|
1![PROGRESS REPORT – TYPE 1 DIABETES TRIALNET TrialNet Progress Report Period – [removed]to[removed]This report reviews the progress made by Type 1 Diabetes TrialNet during the period January 1, 2011 to present. The pu](https://www.pdfsearch.io/img/f6bfbf1e5508251af5dc899d743b10ca.jpg "PROGRESS REPORT – TYPE 1 DIABETES TRIALNET TrialNet Progress Report Period – [removed]to[removed]This report reviews the progress made by Type 1 Diabetes TrialNet during the period January 1, 2011 to present. The pu") | PROGRESS REPORT – TYPE 1 DIABETES TRIALNET TrialNet Progress Report Period – [removed]to[removed]This report reviews the progress made by Type 1 Diabetes TrialNet during the period January 1, 2011 to present. The puAdd to Reading ListSource URL: www.diabetestrialnet.orgLanguage: English - Date: 2012-02-20 13:11:44 |
2![Editorial For reprint orders, please contact [removed] EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good cop? Expert Rev. Clin. Immunol. 9(2), 95–[removed])](https://www.pdfsearch.io/img/251d9a71e7bfd7d0580e28d360b509ef.jpg "Editorial For reprint orders, please contact [removed] EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good cop? Expert Rev. Clin. Immunol. 9(2), 95–[removed])") | Editorial For reprint orders, please contact [removed] EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good cop? Expert Rev. Clin. Immunol. 9(2), 95–[removed])Add to Reading ListSource URL: www.faustmanlab.orgLanguage: English - Date: 2013-12-11 22:21:47 |